<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:40:43Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6189378" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6189378</identifier>
        <datestamp>2018-10-22</datestamp>
        <setSpec>jvim</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Vet Intern Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">J. Vet. Intern. Med</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1939-1676</journal-id>
              <journal-id journal-id-type="publisher-id">JVIM</journal-id>
              <journal-title-group>
                <journal-title>Journal of Veterinary Internal Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0891-6640</issn>
              <issn pub-type="epub">1939-1676</issn>
              <publisher>
                <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>
                <publisher-loc>Hoboken, USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6189378</article-id>
              <article-id pub-id-type="pmcid">PMC6189378</article-id>
              <article-id pub-id-type="pmc-uid">6189378</article-id>
              <article-id pub-id-type="pmid">30084157</article-id>
              <article-id pub-id-type="doi">10.1111/jvim.15289</article-id>
              <article-id pub-id-type="publisher-id">JVIM15289</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Standard Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>EQUID</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Standard Articles</subject>
                    <subj-group subj-group-type="heading">
                      <subject>Respiratory</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Efficacy of tamoxifen for the treatment of severe equine asthma</article-title>
                <alt-title alt-title-type="left-running-head">MAINGUY‐SEERS <sc>et al</sc>.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jvim15289-cr-0001" contrib-type="author">
                  <name>
                    <surname>Mainguy‐Seers</surname>
                    <given-names>Sophie</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4768-6674</contrib-id>
                  <xref ref-type="aff" rid="jvim15289-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jvim15289-cr-0002" contrib-type="author">
                  <name>
                    <surname>Picotte</surname>
                    <given-names>Khristine</given-names>
                  </name>
                  <xref ref-type="aff" rid="jvim15289-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jvim15289-cr-0003" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Lavoie</surname>
                    <given-names>Jean‐Pierre</given-names>
                  </name>
                  <address>
                    <email>jean-pierre.lavoie@umontreal.ca</email>
                  </address>
                  <xref ref-type="aff" rid="jvim15289-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="jvim15289-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Faculty of Veterinary Medicine, Department of Clinical Sciences</named-content>
                <institution>Université de Montréal</institution>
                <named-content content-type="city">St‐Hyacinthe</named-content>
                <named-content content-type="country-part">QC</named-content>
                <country country="CA">Canada</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Jean‐Pierre Lavoie, Faculty of veterinary medicine, Department of Clinical Sciences, 3200 Sicotte Street, St‐Hyacinthe, QC J2S 2M2, Canada.<break/>
Email: <email>jean-pierre.lavoie@umontreal.ca</email><break/></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>07</day>
                <month>8</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <season>Sep-Oct</season>
                <year>2018</year>
              </pub-date>
              <volume>32</volume>
              <issue>5</issue>
              <issue-id pub-id-type="doi">10.1111/jvim.2018.32.issue-5</issue-id>
              <fpage>1748</fpage>
              <lpage>1753</lpage>
              <history>
                <date date-type="received">
                  <day>12</day>
                  <month>9</month>
                  <year>2017</year>
                </date>
                <date date-type="rev-recd">
                  <day>22</day>
                  <month>3</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>26</day>
                  <month>6</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 American College of Veterinary Internal Medicine <copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.</copyright-statement>
                <license license-type="creativeCommonsBy-nc">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JVIM-32-1748.pdf"/>
              <abstract>
                <sec id="jvim15289-sec-0001">
                  <title>Background</title>
                  <p>Tamoxifen, a selective estrogen receptor modulator, decreased airway neutrophilia and improved clinical signs in an experimental model of equine asthma, and induced neutrophilic apoptosis in vitro.</p>
                </sec>
                <sec id="jvim15289-sec-0002">
                  <title>Hypothesis/Objectives</title>
                  <p>Tamoxifen reduces airway neutrophilia and improves lung function in severe asthmatic horses.</p>
                </sec>
                <sec id="jvim15289-sec-0003">
                  <title>Animals</title>
                  <p>Twelve severe asthmatic horses from a research herd.</p>
                </sec>
                <sec id="jvim15289-sec-0004">
                  <title>Methods</title>
                  <p>Randomized controlled blinded study design. The effects of a 12‐day oral treatment with tamoxifen (0.22 mg/kg, q24h) or dexamethasone (0.06 mg/kg, q24h) on lung function, endoscopic tracheal mucus score and bronchoalveolar lavage fluid cytology were compared.</p>
                </sec>
                <sec id="jvim15289-sec-0005">
                  <title>Results</title>
                  <p>Tamoxifen significantly improved the pulmonary resistance (<italic>R</italic>
<sub>L</sub>; mean reduction of 1.15 cm H<sub>2</sub>O/L/s [CI: 0.29‐2.01, <italic>P</italic> = .007] on day 13), but had no effect on the other variables evaluated. Dexamethasone normalized lung function (mean reduction of <italic>R</italic>
<sub>L</sub> of 2.48 cm H<sub>2</sub>O/L/s [CI: 1.54‐3.43, <italic>P</italic> &lt; .0001] on day 13), without affecting airway neutrophilia.</p>
                </sec>
                <sec id="jvim15289-sec-0006">
                  <title>Conclusions and Clinical Importance</title>
                  <p>Results of this study do not support the use of tamoxifen at the dose studied as an antineutrophilic medication in the treatment of asthmatic horses in chronic exacerbation.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="jvim15289-kwd-0001">airway neutrophilia</kwd>
                <kwd id="jvim15289-kwd-0002">dexamethasone</kwd>
                <kwd id="jvim15289-kwd-0003">estrogen</kwd>
                <kwd id="jvim15289-kwd-0004">heaves</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>Canadian Institutes of Health Research</funding-source>
                </award-group>
                <award-group>
                  <funding-source>Equine Research Fund of the Université de Montréal (unrestricted grant from Zoetis)</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="6"/>
                <table-count count="0"/>
                <page-count count="6"/>
                <word-count count="4798"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>component-id</meta-name>
                  <meta-value>jvim15289</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>September/October 2018</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.5.0.1 mode:remove_FC converted:16.10.2018</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jvim15289-cit-9001"><string-name><surname>Mainguy‐Seers</surname><given-names>S</given-names></string-name>, <string-name><surname>Picotte</surname><given-names>K</given-names></string-name>, <string-name><surname>Lavoie</surname><given-names>J‐P</given-names></string-name>. <article-title>Efficacy of tamoxifen for the treatment of severe equine asthma</article-title>. <source xml:lang="en">J Vet Intern Med</source>. <year>2018</year>;<volume>32</volume>:<fpage>1748</fpage>–<lpage>1753</lpage>. <pub-id pub-id-type="doi">10.1111/jvim.15289</pub-id>
</mixed-citation>
              </p>
              <fn-group id="jvim15289-ntgp-0001">
                <fn id="jvim15289-note-0101">
                  <p>
                    <bold>Funding information</bold>
                  </p>
                  <p>Canadian Institutes of Health Research; Equine Research Fund of the Université de Montréal (unrestricted grant from Zoetis)</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body>
            <def-list list-content="abbreviations" id="jvim15289-lp-0001">
              <title>Abbreviations</title>
              <def-item>
                <term id="jvim15289-li-0001">BALF</term>
                <def id="jvim15289-li-0002">
                  <p>bronchoalveolar lavage fluid</p>
                </def>
              </def-item>
              <def-item>
                <term id="jvim15289-li-0003">CI</term>
                <def id="jvim15289-li-0004">
                  <p>95% confidence interval</p>
                </def>
              </def-item>
              <def-item>
                <term id="jvim15289-li-0005">
                  <italic>E</italic>
                  <sub>L</sub>
                </term>
                <def id="jvim15289-li-0006">
                  <p>pulmonary elastance</p>
                </def>
              </def-item>
              <def-item>
                <term id="jvim15289-li-0007">NETs</term>
                <def id="jvim15289-li-0008">
                  <p>neutrophil extracellular traps</p>
                </def>
              </def-item>
              <def-item>
                <term id="jvim15289-li-0009">
                  <italic>P</italic>
                  <sub>L</sub>
                </term>
                <def id="jvim15289-li-0010">
                  <p>transpulmonary pressure</p>
                </def>
              </def-item>
              <def-item>
                <term id="jvim15289-li-0011">
                  <italic>R</italic>
                  <sub>L</sub>
                </term>
                <def id="jvim15289-li-0012">
                  <p>pulmonary resistance</p>
                </def>
              </def-item>
            </def-list>
            <sec id="jvim15289-sec-0007">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Severe equine asthma, also known as heaves or recurrent airway obstruction, is a common and incurable respiratory disease of adult horses. Exacerbations are triggered by inhalation of environmental antigens, most commonly those found in hay. The disease is characterized by airway hyper‐responsiveness, mucus hypersecretion, intraluminal neutrophilia, and structural changes affecting the airways (remodeling).<xref rid="jvim15289-bib-0001" ref-type="ref">1</xref> Through the release of pro‐inflammatory mediators, proteases, and extracellular traps, neutrophils are potentially major perpetuators of lung damage<xref rid="jvim15289-bib-0002" ref-type="ref">2</xref>, <xref rid="jvim15289-bib-0003" ref-type="ref">3</xref> and their presence has been associated with the dysfunction of peripheral airways in asthmatic patients.<xref rid="jvim15289-bib-0004" ref-type="ref">4</xref> Usual therapies (corticosteroids and bronchodilators), while improving the lung function, do not normalize airway luminal neutrophilia and tissue remodeling of asthmatic horses.<xref rid="jvim15289-bib-0005" ref-type="ref">5</xref>, <xref rid="jvim15289-bib-0006" ref-type="ref">6</xref> Furthermore, clinical signs relapse quickly after cessation of medication.<xref rid="jvim15289-bib-0007" ref-type="ref">7</xref> Although antigen avoidance controls airway inflammation, pulmonary remodeling is incompletely reversed even after a year at pasture.<xref rid="jvim15289-bib-0005" ref-type="ref">5</xref> Therefore, therapies targeting airway neutrophilia are required to determine if control of pulmonary inflammation can improve lung function and remodeling in severe equine asthma.<xref rid="jvim15289-bib-0008" ref-type="ref">8</xref>
</p>
              <p>Tamoxifen is a synthetic selective estrogen receptor modulator. Because of its antagonism of estrogen‐dependent growth and its inhibitory effect on breast epithelial cells proliferation, its major use has been in the treatment of breast cancer.<xref rid="jvim15289-bib-0009" ref-type="ref">9</xref>, <xref rid="jvim15289-bib-0010" ref-type="ref">10</xref> Nonetheless, tamoxifen appears to have a broader spectrum of activity as it showed beneficial effects in estrogen‐receptor negative cancers, in selected immune disorders, and potentially in spinal cord injury.<xref rid="jvim15289-bib-0011" ref-type="ref">11</xref>, <xref rid="jvim15289-bib-0012" ref-type="ref">12</xref>, <xref rid="jvim15289-bib-0013" ref-type="ref">13</xref>, <xref rid="jvim15289-bib-0014" ref-type="ref">14</xref> As estrogen administration has been associated with both improvement and, contrariwise, to the development of asthma in women, studying the impact of an estrogen receptor modulator could help delineate the role of sex hormones in asthma.<xref rid="jvim15289-bib-0015" ref-type="ref">15</xref>, <xref rid="jvim15289-bib-0016" ref-type="ref">16</xref> Recently, it showed promising results for the treatment of severe equine asthma by reducing the neutrophilic chemotactic response and respiratory burst production and by inducing apoptosis of peripheral and pulmonary neutrophils in vitro.<xref rid="jvim15289-bib-0017" ref-type="ref">17</xref>, <xref rid="jvim15289-bib-0018" ref-type="ref">18</xref> Tamoxifen was also studied in healthy adult horses in which an asthma‐like inflammation was experimentally reproduced by exposure to <italic>Aspergillus fumigatus</italic> contaminated hay. In this experiment, tamoxifen increased the apoptosis of peripheral and pulmonary neutrophils and improved clinical condition, airway neutrophilia, and mucus accumulation.<xref rid="jvim15289-bib-0019" ref-type="ref">19</xref> We therefore hypothesized that tamoxifen, by decreasing airway neutrophilia, would improve the lung function of severely asthmatic horses. These objectives were to study the effects of tamoxifen on airway luminal inflammation, on tracheal mucus accumulation and on pulmonary function testing of asthmatic horses during continuous antigen exposure.</p>
            </sec>
            <sec id="jvim15289-sec-0008">
              <label>2</label>
              <title>MATERIALS AND METHODS</title>
              <sec id="jvim15289-sec-0009">
                <label>2.1</label>
                <title>Ethics statement</title>
                <p>All experimental procedures were performed in accordance with the Canadian Council for Animal Care guidelines and were approved by the Animal Care Committee of the Faculty of Veterinary Medicine of the Université de Montréal (Protocol # Rech‐1324).</p>
              </sec>
              <sec id="jvim15289-sec-0010">
                <label>2.2</label>
                <title>Animals</title>
                <p>Twelve severe asthmatic horses (7 mares and 5 geldings) from this research herd were studied. Horses were mixed breeds, aged 14 ± 4 years and weighed 514 ± 51 kg. The horses were diagnosed with severe asthma based on history and previous results of pulmonary function and bronchoalveolar lavage fluid (BALF) cytology. These horses had historically &gt;25% neutrophils on BALF cytology and a transpulmonary pressure (<italic>P</italic>
<sub>L</sub>) change above 15 cm of H<sub>2</sub>O when stabled and fed hay and airway obstruction was reversible by antigen avoidance. The presence of a concomitant medical condition was excluded with a physical examination and complete blood count.</p>
                <p>To induce chronic exacerbation of the disease as seen in clinical practice, the animals were stabled 3 weeks before the study and were fed dry timothy hay and sweet feed twice daily. The management remained the same throughout the study period. No treatment was administered at least 7 weeks before the trial. Horses were conditioned to wear a mask and to stand in a stock.</p>
              </sec>
              <sec id="jvim15289-sec-0011">
                <label>2.3</label>
                <title>Pulmonary function tests</title>
                <p>Lung function was measured in standing unsedated animals, except for one horse that required sedation before each pulmonary function test (xylazine [Rompum, Bayer, Mississauga, ON, Canada], 0.4 mg/kg, IV).<xref rid="jvim15289-bib-0006" ref-type="ref">6</xref> Briefly, esophageal pressure was measured as an index of the transpulmonary pressure (<italic>P</italic>
<sub>L</sub>) with a balloon sealed over the end of a polyethylene catheter placed in the distal third of the esophagus. Flow rates were obtained by the use of a heated pneumotachograph and a differential pressure transducer fitted to a mask placed over the horse's nose. The system (Flexiware 7.6, SCIREQ, Montréal, QC, Canada) allowed electronic integration of the flow signal to provide tidal volume. Before each experiment, the system was calibrated by forcing known flow of air through the pneumotachograph with a blower‐rotameter and by applying known pressure with a water manometer on the differential pressure transducer used to measure esophageal pressure. Values of pulmonary resistance (<italic>R</italic>
<sub>L</sub>) and elastance (<italic>E</italic>
<sub>L</sub>) were obtained by applying the data to the multiple regression equation for the single compartment model of the lung (<italic>P</italic>
<sub>L</sub> = <italic>E</italic>
<sub>L</sub>
<italic>V</italic> + <italic>R</italic>
<sub>L</sub>
<italic>V</italic> + <italic>K</italic>) where <italic>V</italic> is the volume, <italic>V</italic> the airflow, and <italic>K</italic> the transpulmonary end‐expiratory pressure. All the valid breaths were used for analysis.</p>
              </sec>
              <sec id="jvim15289-sec-0012">
                <label>2.4</label>
                <title>Endoscopic tracheal mucus scoring and bronchoalveolar lavage</title>
                <p>Horses were sedated with xylazine (Rompum, Bayer, Mississauga, ON, Canada; 0.5 mg/kg, IV) and butorphanol (Torbugesic, Zoetis, Florham Park, New Jersey); 20‐30 μg/kg, IV) and tracheoscopy was performed with a 1.6 m videoendoscope (Evis Exera II CV‐180, Olympus Canada Inc., Richmond Hill, ON, Canada). Tracheal mucus score was evaluated during reviewing of video recordings by an investigator blinded to the treatment group.<xref rid="jvim15289-bib-0020" ref-type="ref">20</xref> Bronchoalveolar lavage was performed as previously described.<xref rid="jvim15289-bib-0006" ref-type="ref">6</xref> Briefly, after topical anesthesia with 0.5% lidocaine (Lurocaine; lidocaine hydrochloride 20 mg/mL, Vétoquinol N.‐A. Inc., , Lavaltrie, QC, Canada), two 250 mL‐boluses of warm sterile isotonic saline (0.9% Sodium Chloride Injection, USP, Baxter, Mississauga, ON, Canada) were sequentially instilled into a main bronchus through the videoendoscope and then aspirated with a suction pump. The samples were kept on ice until reaching the laboratory within 90 minutes. Cytocentrifuged preparations of BALF (400 μL, unfiltered) were made and cells were stained with a modified Wright–Giemsa solution (DiffQuick, Fisher Scientific, Waltham, Massachusetts). Differential leucocyte counts from 400 cells were performed by an investigator blinded to the treatment group.</p>
              </sec>
              <sec id="jvim15289-sec-0013">
                <label>2.5</label>
                <title>Study protocol</title>
                <p>After randomization based on pulmonary resistance ranking value, six horses received tamoxifen citrate (Apo‐tamox, Apotex Inc., Toronto, ON, Canada); 20 mg/tablet, 0.22 mg/kg, PO)<xref rid="jvim15289-bib-0019" ref-type="ref">19</xref> once daily and six horses received dexamethasone<sup>i</sup> (Dexamethasone powder, Dominion Veterinary Laboratories Ltd. Winnipeg, MB, Canada); 10 mg/packet, 0.06 mg/kg, PO) once daily for 12 days. Pulmonary function tests were performed before treatment on day 1, and on days 6 and 13. Endoscopic tracheal mucus scores and bronchoalveolar lavages were performed on days 1 and 13. The attitude, appetite, and a clinical respiratory score<xref rid="jvim15289-bib-0021" ref-type="ref">21</xref> were evaluated daily by a blinded investigator.</p>
              </sec>
              <sec id="jvim15289-sec-0014">
                <label>2.6</label>
                <title>Statistical analysis</title>
                <p>Bronchoalveolar lavage, lung function, and the clinical respiratory score data were analyzed with repeated‐measures two‐way ANOVA with “group” as the between‐subject factor and “time” (days of treatment) as the within‐subject factor with Bonferroni corrections for multiple comparisons. Mucus scores were evaluated within each treatment group with Wilcoxon matched‐pairs signed rank tests and among treatment groups with Mann‐Whitney <italic>U</italic> tests. Data are described as mean difference with 95% confidence interval (CI). <italic>P</italic> values &lt;.05 were considered statistically significant. GraphPad Prism 7 (GraphPad Prism 7, GraphPad Software, Inc, La Jolla, California) was used for statistical calculations.</p>
              </sec>
            </sec>
            <sec id="jvim15289-sec-0015">
              <label>3</label>
              <title>RESULTS</title>
              <p>No adverse effect was observed in the tamoxifen group. On the ninth day of treatment, a horse treated with dexamethasone developed hypocalcemic and hypomagnesemic tetany unresponsive to treatment. Euthanasia was humanely elected for this animal and at necropsy, loss of the principal cells of the parathyroid gland was observed. The exact cause of this finding was undetermined. All data from that horse were excluded from analysis.</p>
              <sec id="jvim15289-sec-0016">
                <label>3.1</label>
                <title>Pulmonary function tests and clinical respiratory scores</title>
                <p>Horses were in clinical exacerbation of the disease at baseline (<italic>P</italic>
<sub>L</sub> &gt; 15 cm H<sub>2</sub>O, <italic>R</italic>
<sub>L</sub> &gt; 1 cm H<sub>2</sub>O/L/s, and <italic>E</italic>
<sub>L</sub> &gt; 1 cm H<sub>2</sub>O/L). A group‐time interaction was noted for the <italic>R</italic>
<sub>L</sub>, <italic>E</italic>
<sub>L</sub>, and <italic>P</italic>
<sub>L</sub> values as dexamethasone significantly improved lung function which normalized in all treated horses when evaluated on day 6 (mean reduction of <italic>R</italic>
<sub>L</sub> of 2.29 cm H<sub>2</sub>O/L/s [CI: 1.35‐3.24, <italic>P</italic> &lt; .0001], mean reduction of <italic>E</italic>
<sub>L</sub> of 4.44 cm H<sub>2</sub>O/L [CI: 2.51‐6.37, <italic>P</italic> &lt; .0001], and mean reduction of <italic>P</italic>
<sub>L</sub> of 32.44 cm H<sub>2</sub>O [CI: 20.69‐44.20, <italic>P</italic> &lt; 0.0001]) and 13 (mean reduction of <italic>R</italic>
<sub>L</sub> of 2.48 cm H<sub>2</sub>O/L/s [CI: 1.54‐3.43, <italic>P</italic> &lt; .0001], mean reduction of <italic>E</italic>
<sub>L</sub> of 4.45 cm H<sub>2</sub>O/L [CI: 2.52‐6.38, <italic>P</italic> &lt; .0001], and mean reduction of <italic>P</italic>
<sub>L</sub> of 34.65 cm H<sub>2</sub>O [CI: 22.89‐46.41, <italic>P</italic> &lt; .0001]; Figures <xref rid="jvim15289-fig-0001" ref-type="fig">1</xref>, <xref rid="jvim15289-fig-0002" ref-type="fig">2</xref>, <xref rid="jvim15289-fig-0003" ref-type="fig">3</xref>). Treatment with tamoxifen had no significant effect on <italic>P</italic>
<sub>L</sub> (mean increase of 2.19 cm H<sub>2</sub>O on day 13 [CI: −12.93 to 8.54, <italic>P</italic> &gt; .99]) and <italic>E</italic>
<sub>L</sub> (mean increase of 1.74 cm H<sub>2</sub>O/L on day 13 [CI: −3.51 to 0.02, <italic>P</italic> = .054]). However, a significant reduction of <italic>R</italic>
<sub>L</sub> was noted at the end of the treatment period with tamoxifen (mean reduction of 1.15 cm H<sub>2</sub>O/L/s [CI: 0.29‐2.01, <italic>P</italic> = .007]). The clinical respiratory scores were improved in the dexamethasone group only, on day 6 (mean reduction of 1.6/8 [CI: 0.2‐3, <italic>P</italic> = .01]), 8 (mean reduction of 1.8/8 [CI: 0.4‐3.2, <italic>P</italic> = .004]), 10 (mean reduction of 1.8/8 [CI: 0.4‐3.2, <italic>P</italic> = .004]), and 11 (mean reduction of 2.2/8 [CI: 0.8‐3.6, <italic>P</italic> = .0002]; Figure <xref rid="jvim15289-fig-0004" ref-type="fig">4</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jvim15289-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <p>Values of transpulmonary pressure (<italic>P</italic>
<sub>L</sub>) on day 1 (before administration of medication), day 6 and day 13 of treatment with tamoxifen (black circles) and dexamethasone (white circles)</p>
                  </caption>
                  <graphic id="nlm-graphic-1" xlink:href="JVIM-32-1748-g001"/>
                </fig>
                <fig fig-type="Figure" xml:lang="en" id="jvim15289-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <p>Values of pulmonary resistance (<italic>R</italic>
<sub>L</sub>) on day 1 (before administration of medication), day 6 and day 13 of treatment with tamoxifen (black circles) and dexamethasone (white circles)</p>
                  </caption>
                  <graphic id="nlm-graphic-3" xlink:href="JVIM-32-1748-g002"/>
                </fig>
                <fig fig-type="Figure" xml:lang="en" id="jvim15289-fig-0003" orientation="portrait" position="float">
                  <label>Figure 3</label>
                  <caption>
                    <p>Values of pulmonary elastance (<italic>E</italic>
<sub>L</sub>) on day 1 (before administration of medication), day 6 and day 13 of treatment with tamoxifen (black circles) and dexamethasone (white circles)</p>
                  </caption>
                  <graphic id="nlm-graphic-5" xlink:href="JVIM-32-1748-g003"/>
                </fig>
                <fig fig-type="Figure" xml:lang="en" id="jvim15289-fig-0004" orientation="portrait" position="float">
                  <label>Figure 4</label>
                  <caption>
                    <p>Daily clinical respiratory scores (means and standard deviations) from day 1 (before administration of medication) to day 13 of treatment with tamoxifen (black circles) and dexamethasone (white circles). *<italic>P</italic> &lt; .05; **<italic>P</italic> &lt; .01; ***<italic>P</italic> &lt; .001 (significant differences from baseline)</p>
                  </caption>
                  <graphic id="nlm-graphic-7" xlink:href="JVIM-32-1748-g004"/>
                </fig>
              </sec>
              <sec id="jvim15289-sec-0017">
                <label>3.2</label>
                <title>Tracheal mucus scores</title>
                <p>No difference was observed in the tracheal mucus scores among treatment groups at baseline or after treatment (mean reduction of 0.8/5 [CI: −2.8 to 1.1, <italic>P</italic> = .56] in the tamoxifen group and mean reduction of 0.5/5 [CI: −2.0 to 1.0, <italic>P</italic> = .75) in the dexamethasone group on day 13; Figure <xref rid="jvim15289-fig-0005" ref-type="fig">5</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jvim15289-fig-0005" orientation="portrait" position="float">
                  <label>Figure 5</label>
                  <caption>
                    <p>Tracheal mucus scores on day 1 (before administration of medication) and day 13 of treatment with tamoxifen (black circles) and dexamethasone (white circles)</p>
                  </caption>
                  <graphic id="nlm-graphic-9" xlink:href="JVIM-32-1748-g005"/>
                </fig>
              </sec>
              <sec id="jvim15289-sec-0018">
                <label>3.3</label>
                <title>BALF cytology</title>
                <p>At the beginning of the study, the percentage of neutrophils in the BALF was above normal (&gt;5%) in 10 of the 11 remaining horses. The horse lacking airway neutrophilia was excluded from analysis concerning BALF cytology. The two‐way ANOVA showed a group effect (<italic>P</italic> = .02) which was possibly related to a higher neutrophilia at baseline in the tamoxifen group. Neither tamoxifen (mean reduction of 17.3% [CI: −15.1 to 49.8, <italic>P</italic> = .35]) nor dexamethasone (mean reduction of 3.3% [CI: −29.2 to 35.7, <italic>P</italic> &gt; .99]) improved the BALF neutrophilia (Figure <xref rid="jvim15289-fig-0006" ref-type="fig">6</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jvim15289-fig-0006" orientation="portrait" position="float">
                  <label>Figure 6</label>
                  <caption>
                    <p>Percentage of each leucocyte population in the bronchoalveolar lavage fluid (BALF) before (day 1) and after treatment (day 13) with tamoxifen (black circles) and dexamethasone (white circles). The left <italic>Y</italic> axis applies to the percentage of neutrophils, macrophages and lymphocytes. The right <italic>Y</italic> axis applies to the percentage of eosinophils and mast cells</p>
                  </caption>
                  <graphic id="nlm-graphic-11" xlink:href="JVIM-32-1748-g006"/>
                </fig>
              </sec>
            </sec>
            <sec id="jvim15289-sec-0019">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>The results of this randomized controlled study failed to detect an effect of a short‐term treatment with tamoxifen on airway neutrophilia in severe asthmatic horses, refuting this hypothesis. A statistically significant diminution, but not a normalization, of airway resistance was observed, without improvement of the pulmonary elastance. As expected, dexamethasone normalized lung function while neither reducing airway inflammation<xref rid="jvim15289-bib-0006" ref-type="ref">6</xref> nor macroscopic mucus accumulation <xref rid="jvim15289-bib-0022" ref-type="ref">22</xref>.</p>
              <p>Tamoxifen's effectiveness in the treatment of breast cancer is partly attributed to the apoptosis of tumor cells mediated by oxidative stress and increased ceramide intracellular level among other mechanisms.<xref rid="jvim15289-bib-0023" ref-type="ref">23</xref> Tamoxifen also causes ceramide intracellular accumulation in neutrophils<xref rid="jvim15289-bib-0024" ref-type="ref">24</xref>, therefore, we suspected that it could lead to neutrophilic apoptosis and concurrent improvement of airway inflammation. However, we did not observe a decrease of airway neutrophilia with tamoxifen which contrasts with previous reports. Indeed, in one study, tamoxifen administered every other day for three doses reduced experimentally induced intraluminal inflammation in healthy horses.<xref rid="jvim15289-bib-0019" ref-type="ref">19</xref> However, the pathways responsible for neutrophil accumulation in healthy horses after hay exposure likely differ from that of asthmatic horses which might explain these different results. In addition, because the airway neutrophilia is transient when hay is introduced to healthy horses and considering that antigenic exposure was ceased when the treatment was initiated, the improvement reported might have been the normal kinetic of airway inflammation regulation, rather than an effect of tamoxifen.<xref rid="jvim15289-bib-0025" ref-type="ref">25</xref> Moreover, the duration of the antigenic challenge was of a short duration (1 week) when compared with this study (3 weeks), which could have contributed the discordance of the results. The chronicity of the exacerbation in this study could have impeded the anti‐inflammatory efficacy of this medication. However, to be useful clinically, a treatment would have to be effective under these conditions.</p>
              <p>The effects of tamoxifen on neutrophils are controversial with in vitro studies suggesting an anti‐inflammatory effect by the induction of apoptosis, a reduction of the chemotactic response and respiratory burst production, a decreased production of 5‐lipoxygenase and a diminution of the neutrophilic infiltration to the site of injury.<xref rid="jvim15289-bib-0017" ref-type="ref">17</xref>, <xref rid="jvim15289-bib-0018" ref-type="ref">18</xref>, <xref rid="jvim15289-bib-0019" ref-type="ref">19</xref>, <xref rid="jvim15289-bib-0026" ref-type="ref">26</xref>, <xref rid="jvim15289-bib-0027" ref-type="ref">27</xref> In contrast, other experiments have shown activation of neutrophils by an enhancement of their chemotaxis, phagocytic and bactericidal activity, and neutrophil extracellular traps (NETs) formation.<xref rid="jvim15289-bib-0024" ref-type="ref">24</xref> Because aberrant NETs production is a feature of human and equine asthma, medications increasing their formation might be detrimental for the treatment of this condition.<xref rid="jvim15289-bib-0003" ref-type="ref">3</xref>, <xref rid="jvim15289-bib-0028" ref-type="ref">28</xref> Furthermore, it has been suggested that the immunomodulation associated with tamoxifen is mediated by a shift from a Th1 to a Th2 response, possibly related to an inhibition of the maturation of dendritic cells.<xref rid="jvim15289-bib-0011" ref-type="ref">11</xref>, <xref rid="jvim15289-bib-0029" ref-type="ref">29</xref> Because a predominant Th2‐type response has been associated with exacerbation in severe equine asthma, at least in some horses <xref rid="jvim15289-bib-0030" ref-type="ref">30</xref>, <xref rid="jvim15289-bib-0031" ref-type="ref">31</xref>, a shift in cellular signaling might explain the lack of efficacy in this study. Of note, a case report describes human asthma exacerbations induced by tamoxifen, but the mechanisms of those deteriorations were not determined.<xref rid="jvim15289-bib-0032" ref-type="ref">32</xref> Taken together, the usefulness of this medication raises interrogations in a disease where immunological pathways involved are complex and incompletely understood.</p>
              <p>The main limitation of this trial is the small number of horses which might have precluded the detection of small differences in the airway neutrophilia, the primary outcome of this study. In addition, the mild neutrophilia (&lt;25%) observed in five horses in the present trial could have reduced our capacity to identify improvement of luminal inflammation. Even though the BALF cytology is a mainstay in asthma diagnosis, the degree and onset of neutrophilic influx might not be constant.<xref rid="jvim15289-bib-0033" ref-type="ref">33</xref> From these five horses, only one had airway neutrophilia defined as normal (&lt;5%) despite its disease being well characterized by being part of the research herd for several years, and the presence of severe airway obstruction (<italic>R</italic>
<sub>L</sub> of 4.3 cm H<sub>2</sub>O/L/s and <italic>E</italic>
<sub>L</sub> of 2.2 cm H<sub>2</sub>O/L) at the onset of the study. Nevertheless, the changes in airway neutrophilia with tamoxifen were inconsistent, and did not lead to normalization in any horses. The sample size was based on power analysis calculated from the Perez's study<xref rid="jvim15289-bib-0019" ref-type="ref">19</xref> results where six animals in each group was sufficient to observe significant improvement in airway inflammation, clinical score, and mucus accumulation with tamoxifen. However, considering the mild reduction of neutrophilia and the variability of the data in the current study, about 30 severe asthmatic animals would have been required to obtain significant result with a power of 80% and alpha set at 0.05. Such a small effect would question the usefulness of this drug for the treatment of severe equine asthma. Finally, we cannot exclude that the lack of improvement because of inappropriate dosage. The dose was chosen because it was reportedly effective at decreasing the airway neutrophilia in experimental airway inflammation in horses and was similar to the dosage used for breast‐cancer treatment.<xref rid="jvim15289-bib-0010" ref-type="ref">10</xref>, <xref rid="jvim15289-bib-0019" ref-type="ref">19</xref> The pharmacokinetics of the molecule is currently studied (G. Morán, personal communication). The results of this study should be interpreted in light of the limitations raised above.</p>
              <p>The clinical significance of the improvement in <italic>R</italic>
<sub>L</sub> with tamoxifen in the present study is difficult to conceptualize because the other parameters of lung function and the clinical respiratory scores were unchanged. Resistance is associated with airflow limitations in central airways. Therefore, it is possible that tamoxifen‐mediated specific bronchodilator effect on central bronchi independently from an effect on airway luminal neutrophils and without improving airflow in the periphery of the lung. Selective estrogen receptor modulators can act as a receptor antagonist or agonist depending on the target cells. Interestingly, estrogen possesses bronchodilator property which might be related to its receptor colocalization with beta‐2 adrenergic receptors in airway smooth muscle cells.<xref rid="jvim15289-bib-0034" ref-type="ref">34</xref> Some studies associate estrogen with improvement of asthma clinical signs or lung function<xref rid="jvim15289-bib-0015" ref-type="ref">15</xref>, whereas others suggest a detrimental effect of this sex hormone<xref rid="jvim15289-bib-0016" ref-type="ref">16</xref>. Therefore, an estrogen‐mediated bronchodilation would be a possible explanation for the reduced <italic>R</italic>
<sub>L</sub> observed in this study, however more research on the role of sex hormones in asthma is required. Alternatively, the bronchodilation could have been mediated by an interaction with calcium‐channels. A reduction of vascular smooth muscle cell contractility has been reported with tamoxifen and the authors suggested that the effect might be related to an inhibition of voltage‐dependant calcium channels.<xref rid="jvim15289-bib-0035" ref-type="ref">35</xref>
</p>
              <p>Consistent with the favorable safety profile of tamoxifen in humans, we did not observe adverse events with a short‐term administration. Reported adverse effects after prolonged use include endometrial cancers and thromboembolic accidents.<xref rid="jvim15289-bib-0009" ref-type="ref">9</xref> The refractory hypocalcemic and hypomagnesemic tetany observed in a dexamethasone treated horse was associated with the loss of principal cells in the parathyroid gland which possibly decreased the production of parathyroid hormone. Because glucocorticoids alter calcium metabolism by increasing urinary excretion and decreasing intestinal absorption, the primary underlying condition might have been worsened by the dexamethasone treatment.<xref rid="jvim15289-bib-0036" ref-type="ref">36</xref>, <xref rid="jvim15289-bib-0037" ref-type="ref">37</xref>
</p>
              <p>In conclusion, a short‐term tamoxifen treatment failed to improve airway inflammation of severely asthmatic horses in chronic exacerbation, precluding the use of this medication at the current posology to assess the role of pulmonary neutrophils in the disease. The treatment resulted in a reduction of <italic>R</italic>
<sub>L</sub>, but in contrast to dexamethasone, the lung function did not normalize. Nevertheless, deciphering the mechanisms responsible for the improvement in lung function of severe asthmatic horses with tamoxifen is of interest and justifies determining its pharmacokinetics for future studies.</p>
            </sec>
            <sec id="jvim15289-sec-0021">
              <title>CONFLICT OF INTEREST DECLARATION</title>
              <p>Authors declare no conflict of interest.</p>
            </sec>
          </body>
          <back>
            <ack id="jvim15289-sec-0020">
              <title>ACKNOWLEDGMENTS</title>
              <p>The authors thank Serena Ceriotti and Amandine Vargas for technical support through this study. This study was performed at the Faculty of Veterinary Medicine of the Université de Montréal. It was supported by the Equine Research Fund of the Université de Montréal and an unrestricted research grant from Zoetis and the Canadian Institutes of Health Research. The results of this study were presented at the 35th VCRS annual symposium, Champaign, IL, USA, October 1‐4<sup>th</sup>, 2017.</p>
            </ack>
            <ack id="jvim15289-sec-0022">
              <title>OFF‐LABEL ANTIMICROBIAL DECLARATION</title>
              <p>Authors declare no off‐label use of antimicrobials.</p>
            </ack>
            <ack id="jvim15289-sec-0023">
              <title>INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION</title>
              <p>All experimental procedures were performed in accordance with the Canadian Council for Animal Care guidelines and were approved by the Animal Care Committee of the Faculty of Veterinary Medicine of the Université de Montréal (Protocol # Rech‐1324).</p>
            </ack>
            <ref-list id="jvim15289-bibl-0001" content-type="cited-references">
              <title>References</title>
              <ref id="jvim15289-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0001"><string-name><surname>Pirie</surname><given-names>RS</given-names></string-name>. <article-title>Recurrent airway obstruction: a review</article-title>. <source xml:lang="en">Equine Vet J</source>. <year>2014</year>;<volume>46</volume>:<fpage>276</fpage>‐<lpage>288</lpage>.<pub-id pub-id-type="pmid">24164473</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0002"><string-name><surname>Ciepiela</surname><given-names>O</given-names></string-name>, <string-name><surname>Ostafin</surname><given-names>M</given-names></string-name>, <string-name><surname>Demkow</surname><given-names>U</given-names></string-name>. <article-title>Neutrophils in asthma—a review</article-title>. <source xml:lang="en">Respir Physiol Neurobiol</source>. <year>2015</year>;<volume>209</volume>:<fpage>13</fpage>‐<lpage>16</lpage>.<pub-id pub-id-type="pmid">25511380</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0003"><string-name><surname>Cote</surname><given-names>O</given-names></string-name>, <string-name><surname>Clark</surname><given-names>ME</given-names></string-name>, <string-name><surname>Viel</surname><given-names>L</given-names></string-name>, et al. <article-title>Secretoglobin 1A1 and 1A1A differentially regulate neutrophil reactive oxygen species production, phagocytosis and extracellular trap formation</article-title>. <source xml:lang="en">PLoS One</source>. <year>2014</year>;<volume>9</volume>:<fpage>e96217</fpage>.<pub-id pub-id-type="pmid">24777050</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0004"><string-name><surname>Farah</surname><given-names>CS</given-names></string-name>, <string-name><surname>Keulers</surname><given-names>LA</given-names></string-name>, <string-name><surname>Hardaker</surname><given-names>KM</given-names></string-name>, et al. <article-title>Association between peripheral airway function and neutrophilic inflammation in asthma</article-title>. <source xml:lang="en">Respirology</source>. <year>2015</year>;<volume>20</volume>:<fpage>975</fpage>‐<lpage>981</lpage>.<pub-id pub-id-type="pmid">25952106</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0005"><string-name><surname>Leclere</surname><given-names>M</given-names></string-name>, <string-name><surname>Lavoie‐Lamoureux</surname><given-names>A</given-names></string-name>, <string-name><surname>Joubert</surname><given-names>P</given-names></string-name>, et al. <article-title>Corticosteroids and antigen avoidance decrease airway smooth muscle mass in an equine asthma model</article-title>. <source xml:lang="en">Am J Respir Cell Mol Biol</source>. <year>2012</year>;<volume>47</volume>:<fpage>589</fpage>‐<lpage>596</lpage>.<pub-id pub-id-type="pmid">22721832</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0006"><string-name><surname>Lavoie</surname><given-names>JP</given-names></string-name>, <string-name><surname>Pasloske</surname><given-names>K</given-names></string-name>, <string-name><surname>Joubert</surname><given-names>P</given-names></string-name>, et al. <article-title>Lack of clinical efficacy of a phosphodiesterase‐4 inhibitor for treatment of heaves in horses</article-title>. <source xml:lang="en">J Vet Intern Med</source>. <year>2006</year>;<volume>20</volume>:<fpage>175</fpage>‐<lpage>181</lpage>.<pub-id pub-id-type="pmid">16496938</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0007"><string-name><surname>Rush</surname><given-names>BR</given-names></string-name>, <string-name><surname>Raub</surname><given-names>ES</given-names></string-name>, <string-name><surname>Rhoads</surname><given-names>WS</given-names></string-name>, et al. <article-title>Pulmonary function in horses with recurrent airway obstruction after aerosol and parenteral administration of beclomethasone dipropionate and dexamethasone, respectively</article-title>. <source xml:lang="en">Am J Vet Res</source>. <year>1998</year>;<volume>59</volume>:<fpage>1039</fpage>‐<lpage>1043</lpage>.<pub-id pub-id-type="pmid">9706210</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0008"><string-name><surname>Leclere</surname><given-names>M</given-names></string-name>, <string-name><surname>Lavoie‐Lamoureux</surname><given-names>A</given-names></string-name>, <string-name><surname>Lavoie</surname><given-names>JP</given-names></string-name>. <article-title>Heaves, an asthma‐like disease of horses</article-title>. <source xml:lang="en">Respirology</source>. <year>2011</year>;<volume>16</volume>:<fpage>1027</fpage>‐<lpage>1046</lpage>.<pub-id pub-id-type="pmid">21824219</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0009"><string-name><surname>Traboulsi</surname><given-names>T</given-names></string-name>, <string-name><surname>El Ezzy</surname><given-names>M</given-names></string-name>, <string-name><surname>Gleason</surname><given-names>JL</given-names></string-name>, et al. <article-title>Antiestrogens: structure‐activity relationships and use in breast cancer treatment</article-title>. <source xml:lang="en">J Mol Endocrinol</source>. <year>2017</year>;<volume>58</volume>:<fpage>R15</fpage>‐<lpage>R31</lpage>.<pub-id pub-id-type="pmid">27729460</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0010"><string-name><surname>Howell</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>SR</given-names></string-name>, <string-name><surname>Howell</surname><given-names>A</given-names></string-name>. <article-title>The use of selective estrogen receptor modulators and selective estrogen receptor down‐regulators in breast cancer</article-title>. <source xml:lang="en">Best Pract Res Clin Endocrinol Metab</source>. <year>2004</year>;<volume>18</volume>:<fpage>47</fpage>‐<lpage>66</lpage>.<pub-id pub-id-type="pmid">14687597</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0011"><string-name><surname>Behjati</surname><given-names>S</given-names></string-name>, <string-name><surname>Frank</surname><given-names>MH</given-names></string-name>. <article-title>The effects of tamoxifen on immunity</article-title>. <source xml:lang="en">Curr Med Chem</source>. <year>2009</year>;<volume>16</volume>:<fpage>3076</fpage>‐<lpage>3080</lpage>.<pub-id pub-id-type="pmid">19689284</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0012"><string-name><surname>Colon</surname><given-names>JM</given-names></string-name>, <string-name><surname>Miranda</surname><given-names>JD</given-names></string-name>. <article-title>Tamoxifen: an FDA approved drug with neuroprotective effects for spinal cord injury recovery</article-title>. <source xml:lang="en">Neural Regen Res</source>. <year>2016</year>;<volume>11</volume>:<fpage>1208</fpage>‐<lpage>1211</lpage>.<pub-id pub-id-type="pmid">27651756</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0013"><string-name><surname>Sereda</surname><given-names>D</given-names></string-name>, <string-name><surname>Werth</surname><given-names>VP</given-names></string-name>. <article-title>Improvement in dermatomyositis rash associated with the use of antiestrogen medication</article-title>. <source xml:lang="en">Arch Dermatol</source>. <year>2006</year>;<volume>142</volume>:<fpage>70</fpage>‐<lpage>72</lpage>.<pub-id pub-id-type="pmid">16415389</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0014"><string-name><surname>Few</surname><given-names>J</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>NW</given-names></string-name>, <string-name><surname>Angelos</surname><given-names>P</given-names></string-name>, <string-name><surname>Simeone</surname><given-names>D</given-names></string-name>, <string-name><surname>Giordano</surname><given-names>T</given-names></string-name>, <string-name><surname>Reeve</surname><given-names>T</given-names></string-name>. <article-title>Riedel's thyroiditis: treatment with tamoxifen</article-title>. <source xml:lang="en">Surgery</source>. <year>1996</year>;<volume>120</volume>:<fpage>993</fpage>‐<lpage>998</lpage>. discussion 998‐999.<pub-id pub-id-type="pmid">8957485</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0015"><string-name><surname>Chandler</surname><given-names>MH</given-names></string-name>, <string-name><surname>Schuldheisz</surname><given-names>S</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>BA</given-names></string-name>, <string-name><surname>Muse</surname><given-names>KN</given-names></string-name>. <article-title>Premenstrual asthma: the effect of estrogen on symptoms, pulmonary function, and beta 2‐receptors</article-title>. <source xml:lang="en">Pharmacotherapy</source>. <year>1997</year>;<volume>17</volume>:<fpage>224</fpage>‐<lpage>234</lpage>.<pub-id pub-id-type="pmid">9085312</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0016"><string-name><surname>Troisi</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Speizer</surname><given-names>FE</given-names></string-name>, <string-name><surname>Willett</surname><given-names>WC</given-names></string-name>, <string-name><surname>Trichopoulos</surname><given-names>D</given-names></string-name>, <string-name><surname>Rosner</surname><given-names>B</given-names></string-name>. <article-title>Menopause, postmenopausal estrogen preparations, and the risk of adult‐onset asthma. A prospective cohort study</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>1995</year>;<volume>152</volume>:<fpage>1183</fpage>‐<lpage>1188</lpage>.<pub-id pub-id-type="pmid">7551368</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0017"><string-name><surname>Borlone</surname><given-names>C</given-names></string-name>, <string-name><surname>Morales</surname><given-names>N</given-names></string-name>, <string-name><surname>Henriquez</surname><given-names>C</given-names></string-name>, et al. <article-title>In vitro effects of tamoxifen on equine neutrophils</article-title>. <source xml:lang="en">Res Vet Sci</source>. <year>2017</year>;<volume>110</volume>:<fpage>60</fpage>‐<lpage>64</lpage>.<pub-id pub-id-type="pmid">28159238</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0018"><string-name><surname>Sarmiento</surname><given-names>J</given-names></string-name>, <string-name><surname>Perez</surname><given-names>B</given-names></string-name>, <string-name><surname>Morales</surname><given-names>N</given-names></string-name>, et al. <article-title>Apoptotic effects of tamoxifen on leukocytes from horse peripheral blood and bronchoalveolar lavage fluid</article-title>. <source xml:lang="en">Vet Res Commun</source>. <year>2013</year>;<volume>37</volume>:<fpage>333</fpage>‐<lpage>338</lpage>.<pub-id pub-id-type="pmid">23846832</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0019"><string-name><surname>Perez</surname><given-names>B</given-names></string-name>, <string-name><surname>Henriquez</surname><given-names>C</given-names></string-name>, <string-name><surname>Sarmiento</surname><given-names>J</given-names></string-name>, et al. <article-title>Tamoxifen as a new therapeutic tool for neutrophilic lung inflammation</article-title>. <source xml:lang="en">Respirology</source>. <year>2016</year>;<volume>21</volume>:<fpage>112</fpage>‐<lpage>118</lpage>.<pub-id pub-id-type="pmid">26510482</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0020"><string-name><surname>Gerber</surname><given-names>V</given-names></string-name>, <string-name><surname>Straub</surname><given-names>R</given-names></string-name>, <string-name><surname>Marti</surname><given-names>E</given-names></string-name>, et al. <article-title>Endoscopic scoring of mucus quantity and quality: observer and horse variance and relationship to inflammation, mucus viscoelasticity and volume</article-title>. <source xml:lang="en">Equine Vet J</source>. <year>2004</year>;<volume>36</volume>:<fpage>576</fpage>‐<lpage>582</lpage>.<pub-id pub-id-type="pmid">15581321</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0021"><string-name><surname>Robinson</surname><given-names>NE</given-names></string-name>, <string-name><surname>Olszewski</surname><given-names>MA</given-names></string-name>, <string-name><surname>Boehler</surname><given-names>D</given-names></string-name>, et al. <article-title>Relationship between clinical signs and lung function in horses with recurrent airway obstruction (heaves) during a bronchodilator trial</article-title>. <source xml:lang="en">Equine Vet J</source>. <year>2000</year>;<volume>32</volume>:<fpage>393</fpage>‐<lpage>400</lpage>.<pub-id pub-id-type="pmid">11037260</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0022"><string-name><surname>Courouce‐Malblanc</surname><given-names>A</given-names></string-name>, <string-name><surname>Fortier</surname><given-names>G</given-names></string-name>, <string-name><surname>Pronost</surname><given-names>S</given-names></string-name>, et al. <article-title>Comparison of prednisolone and dexamethasone effects in the presence of environmental control in heaves‐affected horses</article-title>. <source xml:lang="en">Vet J</source>. <year>2008</year>;<volume>175</volume>:<fpage>227</fpage>‐<lpage>233</lpage>.<pub-id pub-id-type="pmid">17363304</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0023"><string-name><surname>Bekele</surname><given-names>RT</given-names></string-name>, <string-name><surname>Venkatraman</surname><given-names>G</given-names></string-name>, <string-name><surname>Liu</surname><given-names>RZ</given-names></string-name>, et al. <article-title>Oxidative stress contributes to the tamoxifen‐induced killing of breast cancer cells: implications for tamoxifen therapy and resistance</article-title>. <source xml:lang="en">Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>21164</fpage>.<pub-id pub-id-type="pmid">26883574</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0024"><string-name><surname>Corriden</surname><given-names>R</given-names></string-name>, <string-name><surname>Hollands</surname><given-names>A</given-names></string-name>, <string-name><surname>Olson</surname><given-names>J</given-names></string-name>, et al. <article-title>Tamoxifen augments the innate immune function of neutrophils through modulation of intracellular ceramide</article-title>. <source xml:lang="en">Nat Commun</source>. <year>2015</year>;<volume>6</volume>:<fpage>8369</fpage>.<pub-id pub-id-type="pmid">26458291</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0025"><string-name><surname>Leclere</surname><given-names>M</given-names></string-name>, <string-name><surname>Lavoie‐Lamoureux</surname><given-names>A</given-names></string-name>, <string-name><surname>Gelinas‐Lymburner</surname><given-names>E</given-names></string-name>, et al. <article-title>Effect of antigenic exposure on airway smooth muscle remodeling in an equine model of chronic asthma</article-title>. <source xml:lang="en">Am J Respir Cell Mol Biol</source>. <year>2011</year>;<volume>45</volume>:<fpage>181</fpage>‐<lpage>187</lpage>.<pub-id pub-id-type="pmid">20935189</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0026"><string-name><surname>Tavares</surname><given-names>IA</given-names></string-name>, <string-name><surname>Stamford</surname><given-names>IF</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>A</given-names></string-name>. <article-title>Tamoxifen inhibits 5‐lipoxygenase in human polymorphonuclear leucocytes</article-title>. <source xml:lang="en">J Pharm Pharmacol</source>. <year>1987</year>;<volume>39</volume>:<fpage>323</fpage>‐<lpage>324</lpage>.<pub-id pub-id-type="pmid">2884303</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0027"><string-name><surname>Wei</surname><given-names>HY</given-names></string-name>, <string-name><surname>Ma</surname><given-names>X</given-names></string-name>. <article-title>Tamoxifen reduces infiltration of inflammatory cells, apoptosis and inhibits IKK/NF‐kB pathway after spinal cord injury in rats</article-title>. <source xml:lang="en">Neurol Sci</source>. <year>2014</year>;<volume>35</volume>:<fpage>1763</fpage>‐<lpage>1768</lpage>.<pub-id pub-id-type="pmid">24873902</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0028"><string-name><surname>Dworski</surname><given-names>R</given-names></string-name>, <string-name><surname>Simon</surname><given-names>HU</given-names></string-name>, <string-name><surname>Hoskins</surname><given-names>A</given-names></string-name>, <string-name><surname>Yousefi</surname><given-names>S</given-names></string-name>. <article-title>Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways</article-title>. <source xml:lang="en">J Allergy Clin Immunol</source>. <year>2011</year>;<volume>127</volume>:<fpage>1260</fpage>‐<lpage>1266</lpage>.<pub-id pub-id-type="pmid">21315435</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0029"><string-name><surname>Komi</surname><given-names>J</given-names></string-name>, <string-name><surname>Lassila</surname><given-names>O</given-names></string-name>. <article-title>Nonsteroidal anti‐estrogens inhibit the functional differentiation of human monocyte‐derived dendritic cells</article-title>. <source xml:lang="en">Blood</source>. <year>2000</year>;<volume>95</volume>:<fpage>2875</fpage>‐<lpage>2882</lpage>.<pub-id pub-id-type="pmid">10779434</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0030"><string-name><surname>Lavoie</surname><given-names>JP</given-names></string-name>, <string-name><surname>Maghni</surname><given-names>K</given-names></string-name>, <string-name><surname>Desnoyers</surname><given-names>M</given-names></string-name>, et al. <article-title>Neutrophilic airway inflammation in horses with heaves is characterized by a Th2‐type cytokine profile</article-title>. <source xml:lang="en">Am J Respir Crit Care Med</source>. <year>2001</year>;<volume>164</volume>:<fpage>1410</fpage>‐<lpage>1413</lpage>.<pub-id pub-id-type="pmid">11704587</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0031"><string-name><surname>Cordeau</surname><given-names>ME</given-names></string-name>, <string-name><surname>Joubert</surname><given-names>P</given-names></string-name>, <string-name><surname>Dewachi</surname><given-names>O</given-names></string-name>, <string-name><surname>Hamid</surname><given-names>Q</given-names></string-name>, <string-name><surname>Lavoie</surname><given-names>JP</given-names></string-name>. <article-title>IL‐4, IL‐5 and IFN‐gamma mRNA expression in pulmonary lymphocytes in equine heaves</article-title>. <source xml:lang="en">Vet Immunol Immunopathol</source>. <year>2004</year>;<volume>97</volume>:<fpage>87</fpage>‐<lpage>96</lpage>.<pub-id pub-id-type="pmid">14700540</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0032"><string-name><surname>Smith</surname><given-names>RP</given-names></string-name>, <string-name><surname>Dewar</surname><given-names>JA</given-names></string-name>, <string-name><surname>Winter</surname><given-names>JH</given-names></string-name>. <article-title>Tamoxifen‐induced asthma</article-title>. <source xml:lang="en">Lancet</source>. <year>1993</year>;<volume>341</volume>:<fpage>772</fpage>.</mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0033"><string-name><surname>Fairbairn</surname><given-names>SM</given-names></string-name>, <string-name><surname>Page</surname><given-names>CP</given-names></string-name>, <string-name><surname>Lees</surname><given-names>P</given-names></string-name>, et al. <article-title>Early neutrophil but not eosinophil or platelet recruitment to the lungs of allergic horses following antigen exposure</article-title>. <source xml:lang="en">Clin Exp Allergy</source>. <year>1993</year>;<volume>23</volume>:<fpage>821</fpage>‐<lpage>828</lpage>.<pub-id pub-id-type="pmid">10780888</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0034"><string-name><surname>Townsend</surname><given-names>EA</given-names></string-name>, <string-name><surname>Sathish</surname><given-names>V</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>MA</given-names></string-name>, <string-name><surname>Pabelick</surname><given-names>CM</given-names></string-name>, <string-name><surname>Prakash</surname><given-names>YS</given-names></string-name>. <article-title>Estrogen effects on human airway smooth muscle involve cAMP and protein kinase A</article-title>. <source xml:lang="en">Am J Physiol Lung Cell Mol Physiol</source>. <year>2012</year>;<volume>303</volume>:<fpage>L923</fpage>‐<lpage>L928</lpage>.<pub-id pub-id-type="pmid">23002077</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0035"><string-name><surname>Song</surname><given-names>J</given-names></string-name>, <string-name><surname>Standley</surname><given-names>PR</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F</given-names></string-name>, et al. <article-title>Tamoxifen (estrogen antagonist) inhibits voltage‐gated calcium current and contractility in vascular smooth muscle from rats</article-title>. <source xml:lang="en">J Pharmacol Exp Ther</source>. <year>1996</year>;<volume>277</volume>:<fpage>1444</fpage>‐<lpage>1453</lpage>.<pub-id pub-id-type="pmid">8667209</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0036"><string-name><surname>Glade</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Krook</surname><given-names>L</given-names></string-name>, <string-name><surname>Schryver</surname><given-names>HF</given-names></string-name>, <string-name><surname>Hintz</surname><given-names>HF</given-names></string-name>. <article-title>Calcium metabolism in glucocorticoid‐treated pony foals</article-title>. <source xml:lang="en">J Nutr</source>. <year>1982</year>;<volume>112</volume>:<fpage>77</fpage>‐<lpage>86</lpage>.<pub-id pub-id-type="pmid">7054471</pub-id></mixed-citation>
              </ref>
              <ref id="jvim15289-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jvim15289-cit-0037"><string-name><surname>Liamis</surname><given-names>G</given-names></string-name>, <string-name><surname>Milionis</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Elisaf</surname><given-names>M</given-names></string-name>. <article-title>A review of drug‐induced hypocalcemia</article-title>. <source xml:lang="en">J Bone Miner Metab</source>. <year>2009</year>;<volume>27</volume>:<fpage>635</fpage>‐<lpage>642</lpage>.<pub-id pub-id-type="pmid">19730969</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
